The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Production of plant sesquiterpenes in Saccharomyces cerevisiae: Effect of ERG9 repression on sesquiterpene biosynthesis
Open accessAbstract
The yeast Saccharomyces cerevisiae was chosen as a microbial host for heterologous biosynthesis of three different plant sesquiterpenes, namely valencene, cubebol, and patchoulol. The volatility and low solubility of the sesquiterpenes were major practical problems for quantification of the excreted sesquiterpenes. In situ separation of sesquiterpenes in a two‐phase fermentation using dodecane as the secondary phase was therefore performed in order to enable quantitative evaluation of different strains. In order to enhance the availability of the precursor for synthesis of sesquiterpenes, farnesyl diphosphate (FPP), the ERG9 gene which is responsible for conversion of FPP to squalene was downregulated by replacing the native ERG9 promoter with the regulatable MET3 promoter combined with addition of 2 mM methionine to the medium. This strategy led to a reduced ergosterol content of the cells and accumulation of FPP derived compounds like target sesquiterpenes and farnesol. Adjustment of the methionine level during fermentations prevented relieving MET3 promoter repression and resulted in further improved sesquiterpene production. Thus, the final titer of patchoulol and farnesol in the ERG9 downregulated strain reached 16.9 and 20.2 mg/L, respectively. The results obtained in this study revealed the great potential of yeast as a cell factory for production of sesquiterpenes. Biotechnol. Bioeng. 2008;99: 666–677. © 2007 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Production of the antimalarial drug precursor artemisinic acid in engineered yeast
Ro, D.-K., Paradise, E. M., Ouellet, M., Fisher, K. J., Newman, K. L., Ndungu, J. M., Ho, K. A., Eachus, R. A., Ham, T. S., Kirby, J., et al. (2006) · Nature · doi:10.1038/nature04640 · Cited by 2,805
Newman, J. D., Marshall, J., Chang, M., Nowroozi, F., Paradise, E., Pitera, D., Newman, K. L., & Keasling, J. D. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.21017 · Cited by 257 · cited 1×
“Two-phase fermentation has been reported for in situ separation of amorphadiene produced by metabolically engineered E. coli (Newman et al, 2006).”
BackgroundHornby, J. M., Kebaara, B. W., & Nickerson, K. W. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2366-2369.2003 · Cited by 118
Cited by
High-level semi-synthetic production of the potent antimalarial artemisinin
Paddon, C. J., Westfall, P. J., Pitera, D. J., Benjamin, K., Fisher, K., McPhee, D., Leavell, M. D., Tai, A., Main, A., Eng, D., et al. (2013) · Nature · doi:10.1038/nature12051 · Cited by 2,060
Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development
Paddon, C. J., & Keasling, J. D. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3240 · Cited by 675
Hong, K.-K., & Nielsen, J. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0945-1 · Cited by 451
Self-citationTerpenoids: Opportunities for Biosynthesis of Natural Product Drugs Using Engineered Microorganisms
Ajikumar, P. K., Tyo, K., Carlsen, S., Mucha, O., Phon, T. H., & Stephanopoulos, G. (2008) · Molecular Pharmaceutics · doi:10.1021/mp700151b · Cited by 447
Mikkelsen, M. D., Buron, L. D., Salomonsen, B., Olsen, C. E., Hansen, B. G., Mortensen, U. H., & Halkier, B. A. (2012) · Metabolic Engineering · doi:10.1016/j.ymben.2012.01.006 · Cited by 307
Metadata
- Authors
- Asadollahi, M. A., Maury, J., Møller, K., Nielsen, K. F., Schalk, M., Clark, A., & Nielsen, J.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2007-08-17
- Volume
- 99
- Issue
- 3
- Pages
- 666-677
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2128897939
- Cited by
- 241
- References
- 3
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.